GlassScriptPhysician profile
Samuel Y Bae
NPI 1760443139
$5,463.02
in general payments reported to CMS, 2019-2025
60 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $467 · 2021: $774 · 2022: $823 · 2023: $1,035 · 2024: $475 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,403 · Education: $29.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.82 |
| Education | $29.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $402.20 | 2019-2025 | Entyvio, Trintellix |
| Abbvie INC. | $341.21 | 2019-2025 | Rinvoq, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.97 | 2019-2023 | Xifaxan, Trulance |
| Intuitive Surgical, INC. | $321.04 | 2021-2023 | Da Vinci Surgical System |
| Novo Nordisk INC | $263.78 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $185.23 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $173.39 | 2020-2024 | Omvoh, Taltz, Jardiance |
| Janssen Pharmaceuticals, INC | $172.64 | 2019-2021 | |
| Baxter Healthcare | $162.47 | 2023 | Hillrom - Eli 280, Hillrom - Eli 380 |
| Madrigal Pharmaceuticals | $159.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Penumbra, INC. | $158.55 | 2025 | Indigo System |
| Olympus America INC. | $150.35 | 2019-2025 | Hanarostent Esophagus Tts(Ccc) |
| Ferring Pharmaceuticals INC. | $150.16 | 2019-2023 | Rebyota |
| Redhill Biopharma INC. | $146.08 | 2020-2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $140.31 | 2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.